NCT02097108View on ClinicalTrials.gov

Changes in Lipids and Lipoproteins in HIV Infected Women After Switch From Protease Inhibitor to Raltegravir

PHASE2CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

May 31, 2014

Primary Completion Date

December 31, 2015

Study Completion Date

December 31, 2015

Conditions

HIV Infections

Interventions

DRUG

Raltegravir

Trial Locations (3)

1090

AKH Wien, Vienna

1140

Ottto Wagner Spital, Vienna

5020

PMU Salzburg, Salzburg

All Listed Sponsors

collaborator

Merck Sharp & Dohme LLC

INDUSTRY

lead

Arbeitsgemeinschaft medikamentoese Tumortherapie

OTHER

NCT02097108 - Changes in Lipids and Lipoproteins in HIV Infected Women After Switch From Protease Inhibitor to Raltegravir | Biotech Hunter | Biotech Hunter